Ultimate DAPT Trial Principal Results - Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.
In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.
Subscribe to ACCEL Lite
Other ACC resources on DAPT and bleeding risk:
1.      One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes - IVUS-ACS/ULTIMATE-DAPT
2.      Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention
3.      ACC.24 Presentation Slides | ULTIMATE-DAPT